Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | TYMS | P04818 | 5/20 | 0.36 |
| ▸ | TYMP | P19971 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27206891 | 1.00 | HSP90AA1 (0.40) | HSP90AA1TYMSTYMPLMNASMN1; SMN2 | |
| SCHEMBL28600193 | 0.93 | RNASE1 (0.40) | TYMSTYMPRNASE1 | |
| SCHEMBL2031822 | 0.93 | RNASE1 (0.40) | TYMSTYMPRNASE1 | |
| SCHEMBL14771517 | 0.93 | RNASE1 (0.40) | TYMSTYMPRNASE1 | |
| SCHEMBL22984007 | 0.93 | RNASE1 (0.40) | TYMSTYMPRNASE1 | |
| SCHEMBL24263898 | 0.93 | TYMS (0.35) | HSP90AA1TYMSTYMPRNASE1 | |
| SCHEMBL9550769 | 0.93 | RNASE1 (0.40) | TYMSTYMPRNASE1 | |
| SCHEMBL13901245 | 0.93 | RNASE1 (0.40) | TYMSTYMPRNASE1 | |
| SCHEMBL13930549 | 0.93 | RNASE1 (0.40) | TYMSTYMPRNASE1 | |
| SCHEMBL13952067 | 0.93 | RNASE1 (0.40) | TYMSTYMPRNASE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062440-A1 | Multiplex Dye Compounds | LIFE TECHNOLOGIES CORP (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4673453-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS FOR RNA INTERFERENCE AND METHODS RELATING THERETO | Wave Life Sciences Ltd. (SG) | 2026-01-07 | — | — | EP | disclosed |
| US-20250382617-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS FOR RNA INTERFERENCE AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2025-12-18 | — | — | US | disclosed |
| WO-2025235911-A2 | INHIBIN SUBUNIT BETA E-RELATED DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2025-11-13 | — | — | WO | disclosed |
| EP-4547758-A1 | MULTIPLEX DYE COMPOUNDS | Life Technologies Corporation (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119768474-A | Multiple dye compounds | 生命科技股份有限公司 | 2025-04-04 | — | — | CN | disclosed |
| EP-4479406-A1 | OXAZINE DYES AND THEIR USE IN NUCLEIC ACID AMPLIFICATION REACTIONS | Promega Corporation (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2024182749-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS FOR RNA INTERFERENCE AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2024-09-06 | — | — | WO | disclosed |
| WO-2024006477-A1 | MULTIPLEX DYE COMPOUNDS | Life Technologies Corporation (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230340007-A1 | OSCILLATING FLUIDIZED BED OLIGONUCLEOTIDE SYNTHESIZER | ELI LILLY AND COMPANY | 2023-10-26 | — | — | US | disclosed |
| US-20230278968-A1 | OXAZINE DYES AND THEIR USE IN NUCLEIC ACID AMPLIFICATION REACTIONS | PROMEGA CORPORATION | 2023-09-07 | — | — | US | disclosed |
| WO-2023159042-A1 | OXAZINE DYES AND THEIR USE IN NUCLEIC ACID AMPLIFICATION REACTIONS | PROMEGA CORPORATION (US) | 2023-08-24 | — | — | WO | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| EP-4153747-A2 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | Wave Life Sciences Ltd. (SG) | 2023-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278968-A1 | OXAZINE DYES AND THEIR USE IN NUCLEIC ACID AMPLIFICATION REACTIONS | POLRMT, POLB, POLN | HSP90AA1 2985/4885TYMS 33/4885TYMP 8/4885 |
| US-20260062440-A1 | Multiplex Dye Compounds | CCR7, NSUN2, SLC43A1 | HSP90AA1 3045/4885TYMS 775/4885TYMP 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.